• clinical
  • Resolving the spatial and temporal heterogeneity of subclones with cancer driver events may offer insight into therapy response, tumor evolutionary histories and clinical trial design. (biomedcentral.com)
  • We also describe how subclonal diversity might contribute to the limitations of targeted therapies and how it can be leveraged to study the evolutionary history of a tumor and to optimize clinical trial design. (biomedcentral.com)
  • results
  • These results indicate that regulation of beta-catenin is critical to APC's tumor suppressive effect and that this regulation can be circumvented by mutations in either APC or beta-catenin. (labome.org)
  • Results of chi-squared test indicated that there was a significant difference in methylation rate (P less than 0.05), that is, the methylation rate of negatively expressed CHD5 protein was obviously higher than positively expressed protein. (onctoday.com)
  • provides
  • The subclonal diversity within a tumor if viewed as a snapshot, rather than longitudinally, provides little information about the future evolutionary routes that subclonal populations might take. (biomedcentral.com)
  • complex
  • The data suggest that Amer1 exerts its negative regulatory role in Wnt signaling by acting as a scaffold protein for the β-catenin destruction complex and promoting stabilization of Axin at the plasma membrane. (xenbase.org)